Sector pursuit field 15 · Health, care and housing
Our basic working position: This is the first position we would test—not the final bid position. It changes with every buyer organisation, procurement or commercial team, evaluator group, operational user, budget owner and other stakeholder. The live opportunity, people, documents, conversations and clarifications determine the final pursuit.
Public and private contract pursuit
Same capability. Different buying system.
A medical devices and diagnostics pitch cannot be carried unchanged from a published public competition into a private sourcing decision. The solution may be similar, but authority, visibility, negotiation, risk appetite and the people shaping the decision can be very different.
Follow the declared route—and the decision behind it.
Start with the live notice, conditions, evaluation model, timetable, clarification rules and contract.
- Confirm whether the purchase is goods, services or a mixed managed-service arrangement and whether a framework call-off is mandatory or optional.
- Map the device's exact market route for Great Britain and Northern Ireland; do not use a single UK-wide conformity statement.
Find the real buying group and approval path.
Private hospitals, laboratories, distributors and life-science companies use capital purchases, reagent-rental models, managed equipment services, pilots and distribution agreements.
- Establish who initiated the purchase, who owns the budget, who can veto it and how procurement, legal and finance will shape the agreement.
- Test incumbent relationships, negotiation room, approval gates, commercial risk and the evidence each decision-maker needs.
- Use conversations lawfully available in the process to refine the proposition; do not assume a private RFP reveals every deciding factor.
The “buyer” is rarely one person.
Align clinicians, laboratory or theatre users, biomedical engineering, procurement, finance, IT, infection control and regulatory leads.
Sector roles to test: Clinical lead; Laboratory or biomedical scientist; Medical engineering; Digital and cyber assurance; Procurement and finance.
The bidder is ready; the response needs precision.
Use focused writing when the medical devices and diagnostics offer, price, delivery model, responsibilities and approved evidence already withstand challenge. We then align them to the question, stakeholder, evaluation logic and response architecture without pretending prose can repair the underlying business.
Strengthen the bidder, then build the bid.
Use end-to-end management when qualification, solution design, process, team, partners, evidence, commercial logic or mobilisation still needs work. The pursuit becomes a project: gaps are exposed, capability is implemented, owners decide and the written answer grows from a stronger operating position.
Candidate lifecycle movements: Discover → Design → Prove → Deliver. Useful operating lenses to test include Ordnung (controlled structure), Übergabereife (handover readiness) and continuous improvement. They are selected proportionately; they are not certification claims or a substitute for the live contract.
Explore Achmed Esser's Assurance & Delivery Lattice →Relevant practice here can include customer requirements, solution development, evidence planning, proposal reviews and mobilisation hand-off. We apply the parts that fit the pursuit rather than forcing every competition through one template.
See APMP's winning-business lifecycle →Sector position and current context
Public evidence The UK Medical Devices Regulations 2002 remain the core domestic framework as amended. New Great Britain post-market surveillance provisions took effect on 16 June 2025 for devices placed on the GB market from that date, while Northern Ireland continues to follow a distinct route described by MHRA. [ 001, 002, 003, 004 ]
Evidence-linked insight · What this changes The practical bid consequence is continuous evidence maintenance. A historic technical file extract or inherited conformity sentence cannot safely answer a 2026 procurement unless it matches the offered model, intended purpose, risk class, certification route, market, manufacturer role and placement date. [ 002, 004, 005 ]
Where we would start first Create a regulatory baseline for every SKU and configuration in scope. Record classification, intended purpose, conformity evidence, approved or notified body where relevant, registration, representative, UDI, labelling, market, transition basis, PMS outputs and document expiry. Have a qualified specialist approve it before submission. [ 001, 002 ]
Separate products, services and settings
Public evidence Official policy defines medtech broadly, including general devices, active implants, in vitro diagnostics and associated digital tools. Current procurements range from patient-assessment products and point-of-care tests to angiography suites, laboratory robots, diagnostic software, consumables, training and maintenance. [ 007, 010, 011, 012, 013 ]
Evidence-linked insight · What this changes That breadth makes a generic sector answer risky. A low-risk ward device, connected diagnostic analyser and major imaging installation have different clinical users, evidence burdens, infrastructure, consumable dependencies, information flows, acceptance tests and failure consequences even when a framework groups them together. [ 010, 011, 012 ]
Where we would start first Build the scope from buyer use cases rather than catalogue headings. Map each product, accessory, reagent, control, software component, interface, installation task, training package, maintenance service and disposal duty to the responsible entity, price line, acceptance criterion and governing evidence.
Buyers and routes to market
Public evidence The evidence set shows national NHS Supply Chain frameworks, single-trust competitions, collaborative pathology buying and local awards. NICE's HealthTech programme separately evaluates clinical and cost effectiveness for selected non-medicine technologies; it is not the procurement route for every device. [ 006, 010, 011, 012, 014 ]
Evidence-linked insight · What this changes Access and adoption are different gates. A supplier may have lawful market access but no suitable framework position, a framework award but no call-off, or a local purchase without the clinical-change sponsorship needed for sustainable use. The pursuit must locate the actual decision path. [ 006, 007, 010 ]
Where we would start first Map contracting authority, funding source, framework owner, catalogue or further-competition route, clinical sponsor, budget holder and governance approvals. Verify lot scope and user eligibility against the framework documents. For innovations, distinguish regulatory approval, NICE evaluation, commissioning and local adoption milestones. [ 006, 009, 010 ]
What prevents awards
Public evidence Live notices expose requirements beyond supply: installation, emergency-diagnostics automation, long support periods, advanced software, pathology traceability and network-wide use. MHRA guidance also requires a structured post-market system, reporting and corrective-action capability appropriate to the product. [ 004, 011, 013, 014 ]
Evidence-linked insight · What this changes Common award barriers include a mismatched certificate, ambiguous offered configuration, unproven interoperability, incomplete cyber answers, weak clinical evidence, underestimated estates work, fragile consumable supply, vague uptime remedies and savings models that ignore implementation, training or repeat testing. [ 004, 011, 012, 014 ]
Where we would start first Run a product-level compliance gate before solution development. Test mandatory certificates, declarations, registrations, standards, insurance, exclusions, interface compatibility, data location, vulnerability process, sample or demonstration obligations, service coverage and supply capacity. Document any equivalence claim and the authority that can approve it.
Hard prerequisites before the pursuit
Public evidence MHRA's general guidance identifies certification, conformity marking and registration as distinct parts of the UK system. NICE's HealthTech manual evaluates products with appropriate regulatory approval, and the reviewed procurement records describe concrete device classes, technical applications and delivery contexts. [ 002, 006, 010, 013 ]
Evidence-linked insight · What this changes A roadmap to obtain essential approval after award rarely repairs an eligibility gap unless the tender expressly permits it. Likewise, a distributor cannot quietly assume manufacturer obligations, and a subcontracted service desk cannot substitute for a documented vigilance and field-action chain. [ 001, 002, 004 ]
Where we would start first Freeze an offered-product register before final qualification. Link every line to evidence of lawful supply, manufacturer authorisation, relevant standards, product liability, quality management, service competence, import or representative role, incident contact, critical-component capacity and support coverage for the proposed contract term. [ 002, 004 ]
Build the buyer's evidence chain
Public evidence NICE's current programme manual says HealthTech recommendations are based on clinical and cost effectiveness. DHSC policy frames medtech around the right product, price and place, with resilience and continuity of supply among its priorities. Those are connected but separate evidence questions. [ 006, 007 ]
Evidence-linked insight · What this changes A strong proposition follows the patient and operational pathway: population and comparator, device function, test or treatment consequence, user task, output interpretation, downstream capacity, adverse event, stock dependency, maintenance intervention and economic effect. Skipping a link turns benefit into assertion. [ 006, 007, 012 ]
Where we would start first Construct a claim ledger with one row per material promise. Record claim, population, setting, comparator, metric, evidence type, study limitation, local assumption, commercial impact and approved wording. Separate published evidence from internal verification and from projections requiring buyer validation.
Evaluation themes and answer design
Public evidence Procurement examples combine quality and commercial tests across equipment, accessories, software and services. The patient-assessment framework contains numerous lots and suppliers, while the angiography award bundles specialised diagnostic assets with supporting services. Point-of-care procurement adds laboratory governance to near-patient use. [ 010, 011, 012 ]
Evidence-linked insight · What this changes Evaluators need to compare like with like despite product variation. Answers therefore work best when they make the baseline configuration explicit, identify optional features, distinguish included from chargeable lifecycle items, and trace performance claims to reproducible evidence under the intended conditions. [ 010, 011 ]
Where we would start first Use a requirement-to-evidence matrix covering regulatory, clinical, technical, usability, implementation, maintenance, supply, sustainability and price criteria. For each answer state the offered configuration, responsible role, method, frequency, exception route, measure and attachment. Remove unrequested innovation that introduces unmanaged risk.
The full decision group
Public evidence The procurements reviewed involve clinical equipment, pathology, capital assets, software, installation and multi-organisation networks. NICE evaluation also uses evidence and stakeholder input. These settings necessarily extend decision making beyond a procurement officer and an account manager. [ 006, 011, 012, 014 ]
Evidence-linked insight · What this changes Clinical leads judge patient consequence; laboratory teams test quality and traceability; medical engineering examines maintenance; digital teams examine integration and cyber risk; estates teams assess utilities and space; infection specialists review decontamination; finance and procurement test whole-life value and contract remedies. [ 011, 013, 014 ]
Where we would start first Create an approval map tied to the implementation sequence. Identify who specifies, evaluates, validates, signs clinical safety, approves connectivity, accepts equipment, releases users, monitors performance and authorises changes. Tailor evidence packs to those decisions while keeping one controlled product baseline.
Whole-life commercial model
Public evidence Current opportunities span framework goods, equipment with services, point-of-care systems and laboratory automation with a contract horizon potentially reaching ten years. Those forms imply different mixes of capital, consumables, licences, maintenance, upgrades and usage risk. [ 010, 011, 012, 013 ]
Evidence-linked insight · What this changes The apparent unit price can be a small part of buyer cost. Site preparation, interfaces, validation, controls, reagent wastage, repeat tests, staff time, downtime, loan equipment, software support, consumable inflation and decommissioning determine the credible commercial comparison. [ 011, 012, 013 ]
Where we would start first Build a transparent total-cost model against the buyer's expected volumes and service life. Show included quantities, price indices, minimums, shelf life, delivery frequency, maintenance levels, uptime calculation, exclusions, upgrade assumptions and exit costs. Sensitise utilisation, exchange rates and component shortage.
Mobilisation from site survey to safe use
Public evidence Liverpool Women's procurement included installation of an autonomous laboratory robot for emergency diagnostics and a long operational horizon. The pathology archive opportunity involved several trusts and a need to reduce misfiling and loss. Both require controlled change, not simple box delivery. [ 013, 014 ]
Evidence-linked insight · What this changes Go-live risk sits across estates, interfaces, configuration, validation, data migration, stock, standard operating procedures, competency and fallback. A device can be technically installed yet clinically unusable if acceptance evidence, user release or downstream workflow is incomplete. [ 012, 013, 014 ]
Where we would start first Plan acceptance by milestone: design freeze, site readiness, delivery inspection, installation qualification, interface testing, operational and performance qualification, user competency, stock readiness, safety sign-off and controlled cutover. Define rollback, parallel running, hypercare, unresolved-defect treatment and final documentation handover.
Cybersecurity, circularity and safe design
Public evidence DHSC's medtech strategy links access with resilience and sustainable value, while the Design for Life roadmap promotes a move away from linear product use. Neither policy removes product-safety, intended-purpose or regulatory controls when reuse, refurbishment or remanufacture is considered. [ 007, 008 ]
Evidence-linked insight · What this changes Connected devices add lifecycle cyber exposure: identity, interfaces, remote support, software bills of material, patches, unsupported operating systems and vulnerability disclosure. Environmental improvement also needs product-specific evidence, since a lighter footprint cannot compensate for contamination, accuracy or availability risk. [ 007, 008, 011 ]
Where we would start first Submit a secure-configuration and update plan linked to clinical change control and incident response. Quantify packaging, energy, consumables, repairability and take-back where evidence exists. Mark circular options that need regulatory assessment, validated decontamination or revised conformity work before adoption. [ 008 ]
Consortium, manufacturer and service-chain control
Public evidence Large medtech procurements can include manufacturers, distributors, software suppliers, installers, maintenance providers and logistics operators. The NHS Supply Chain device framework lists many suppliers, and capital-equipment awards combine products and supporting services across defined lots. [ 010, 011 ]
Evidence-linked insight · What this changes The buyer experiences one safety and continuity chain even where several legal entities deliver it. Ambiguity over complaint intake, reportability assessment, field action, patch approval, spare parts, loan equipment or end-of-life notice can delay action when patient risk is emerging. [ 004, 010, 011 ]
Where we would start first Create a manufacturer-to-user responsibility matrix. Contractually define document supply, training, installation, vigilance, complaint escalation, corrective action, cybersecurity, inventory traceability, service parts, audit, business continuity, substitution and termination. Verify upstream commitments survive the proposed NHS contract term. [ 004 ]
Performance from device output to pathway effect
Public evidence NICE evaluates clinical and cost effectiveness, and MHRA post-market requirements concern ongoing safety and performance after market placement. Procurement records add operational needs such as emergency diagnostics, point-of-care testing and secure long-term archiving. [ 004, 006, 012, 013, 014 ]
Evidence-linked insight · What this changes Device uptime, analytical accuracy and pathway outcome occupy different levels. A supplier should not claim reduced length of stay from a faster result unless the downstream clinical process, capacity and study evidence support that causal connection. Operational proxies need honest labels. [ 006, 012 ]
Where we would start first Define a balanced measure set: availability, response, first-time fix, consumable fulfilment, error and repeat rates, quality-control exceptions, user competency, incident timeliness, patient or pathway outcome and economic impact. State data source, denominator, exclusions and attribution limit for every metric.
Failure patterns and strengthening sequence
Public evidence MHRA's 2026 material distinguishes current rules from future reform, and its PMS guidance separates device categories and reporting outputs. The procurement sample likewise shows materially different product and service forms. Both reject a one-size-fits-all evidence pack. [ 004, 005, 010, 013 ]
Evidence-linked insight · What this changes Weak bids usually leap from product feature to NHS benefit. Missing steps include the correct configuration, regulatory route, clinical comparator, user workflow, integration, supply dependencies, service response, implementation cost and post-market feedback. Each omission weakens both quality and price credibility. [ 006, 007 ]
Where we would start first Strengthen in order: classify the offer and market; clear mandatory evidence; map clinical use; validate technical fit; model supply and lifecycle cost; build acceptance-led mobilisation; connect PMS; then run independent regulatory, clinical, cyber and commercial red teams on the final baseline.
How Bid Champions supports a device pursuit
Public evidence The public record can establish law, regulatory guidance, policy, evaluation methods and procurement examples. It cannot establish the offered device's compliance, accuracy, cybersecurity, clinical benefit, manufacturing quality, stock position or savings for a particular buyer. [ 001, 002, 006, 010 ]
What this changes Bid intervention has greatest leverage at the joins: turning technical evidence into evaluator-ready answers, finding contradictions between configuration and price, exposing an unsupported benefit claim, or making implementation and service commitments measurable without trespassing into regulatory sign-off.
Where we would start first Bid Champions can lead qualification structure, evidence mapping, story and answer design, work-package integration, commercial challenge, mobilisation narrative and red-team review. Regulatory, clinical, quality, health-economic and cybersecurity approvals must remain with competent accountable specialists.
Retain a controlled product-to-bid system
Public evidence The regulatory and procurement landscape changes across device classes, markets and buying routes. MHRA's reform roadmap is staged, and NHS procurements can move from national framework to network or trust-level competition with different evidence emphasis. [ 005, 010, 012, 014 ]
What this changes A reusable answer library without configuration control is a liability. The more valuable asset is a versioned evidence graph linking products, certificates, studies, standards, incidents, service levels, integrations, costs, authors, approvals and expiry dates to controlled claims.
Where we would start first Maintain a product credential ledger, claim library, market-route table, study summaries, integration patterns, service evidence, supply risk register, cost model, mobilisation modules and permissioned case studies. Trigger review when a device, label, software version, certificate, regulation or critical supplier changes.
Procurement evidence used
Public evidence The procurement sample covers five distinct buying contexts: a national patient-assessment framework, an angiography framework, a point-of-care award, a single-trust laboratory robot and a multi-trust pathology archive. Publication dates range from July 2025 to February 2026. [ 010, 011, 012, 013, 014 ]
Evidence-linked insight · What this changes The sample supports conclusions about variety, lifecycle scope and stakeholder complexity. It does not establish current open opportunities, universal evaluation criteria, market price, product equivalence or clinical superiority. Award values must not be divided into invented unit benchmarks. [ 010, 011, 012, 013, 014 ]
Where we would start first For a live pursuit, assemble the full notice family, lot and framework documents, specifications, response schedules, interface information, activity data, clarification answers, policies, prior awards and implementation constraints. Archive permitted versions and record exactly which evidence supports each final answer.
Relevant anonymised case study
Securing a multi-million-pound public-sector award for clinical diagnostic technology supply
An anonymised Bid Champions client was selected by Department of Health and Social Care programme to provide clinical diagnostic technology supply. The public award record places the opportunity in the £5m–£9.9m band.
- Buyer
- Department of Health and Social Care programme
- Published value band
- £5m–£9.9m
- Outcome
- Contract award recorded
The precise tender-support workstream is confidential. The full case separates Bid Champions’ recorded support, the client’s solution and commitments, and the buyer’s award decision.
Read the complete case studyLive-pursuit check
What we would verify before fixing the strategy.
For a live opportunity, we would recheck the applicable law and standards, the buyer's latest notice and documents, qualification route, amendments, commercial assumptions and delivery conditions. This keeps the analysis useful without treating a general market position as a substitute for the actual competition.
Priority public records to recheck: Regulating medical devices in the UK; Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024; Medical devices post-market surveillance: introduction and scope; Implementation of the future regulation of medical devices.
Independent verification checks
The public references supporting the evidence points above remain available so a bidder, specialist or decision-maker can test the position against the original authority.
Open 14 public references used to test this sector position
- Medical Devices Regulations 2002 — The National Archives
- Regulating medical devices in the UK — Medicines and Healthcare products Regulatory Agency
- Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 — The National Archives
- Medical devices post-market surveillance: introduction and scope — Medicines and Healthcare products Regulatory Agency
- Implementation of the future regulation of medical devices — Medicines and Healthcare products Regulatory Agency
- NICE HealthTech programme manual — National Institute for Health and Care Excellence
- Medical technology strategy — Department of Health and Social Care
- Design for Life roadmap — Department of Health and Social Care
- Procurement Act 2023 — The National Archives
- Total Patient Assessment Device Solutions — NHS Supply Chain
- Angiography, Hybrid Theatres, Capital Equipment, Related Accessories and Services — NHS Supply Chain
- Glucose and Ketone Testing at Point of Care — University Hospitals of North Midlands NHS Trust
- Autonomous Laboratory Robot System — Liverpool Women's NHS Foundation Trust
- North East and North Cumbria Pathology Archiving System — North East and North Cumbria Pathology Network